In a recent article for Pharmacy Times, RxBenefits Chief Pharmacy Officer Mark Campbell, PharmD, explores the challenges that have prevented biosimilars from delivering on their cost-saving promise.
Campbell highlights how – despite the high expectations for biosimilars to drive down the price of expensive biologics like Humira – market dynamics, formulary challenges, and high introductory pricing have limited adoption and the competition necessary to lower prices.
Key Highlights:
- The complex market dynamics preventing biosimilar uptake
- The role of PBM formularies in maintaining high costs
- Why biosimilars have not generated the expected savings
- What needs to change for biosimilars to fulfill their potential
